Welcome

On behalf of the Local Organizing Committee I am delighted to welcome you to the 2014 EASDec Annual Meeting in Padova. Exciting new findings in clinical and basic research of diabetic retinopathy and other diabetic eye complications will be presented during our 24th EASDec Meeting. A special workshop will be dedicated to corneal confocal microscopy as a biomarker of peripheral diabetic neuropathy. EASDec meeting also provides a fruitful opportunity to interact and discuss new ideas of our research field and questions related to daily clinical practice. We hope you will enjoy your stay in Padova and have enough time to experience the atmosphere of our city.

Edoardo Midena
Chairman, Local Organizing Committee

About EASDec

EASDec - EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES
Eye Complications Study Group (EASDec)

EASDec is a Study Group of the European Association for the Study of Diabetes (EASD) with special responsibility for the study of the eye complications of diabetes. Its aim is to promote the advancement of knowledge of all aspects of diabetic retinopathy, including epidemiology, pathology, pathophysiology, investigation and treatment through active collaboration between ophthalmologists and diabetologists. The ultimate goal of the Group is to prevent the development of diabetic retinopathy and to search for the best treatment of this condition in diabetic patients.

EASDec Board

Professor Massimo Porta, Turin, Italy
Professor Simon Harding, Liverpool, UK
Professor Rafael Simó, Barcelona, Spain
Professor Tunde Peto, London, UK
Professor Reinier O. Schlingemann, Amsterdam, NL
EASDec 2014
European Association for the Study of Diabetes
Eye Complications Study Group (EASDec)

24th ANNUAL MEETING

15th - 17th May 2014, Padova, Italy

Under the patronage of
15th MAY 2014, Thursday
at Palazzo del Bo, Padova

16.00 - 19.00 Registration

**Satellite Symposium:**

17.00 - 18.00 Diabetic macular edema: a comprehensive approach
Chairs: *Professors Edoardo Midena and Massimo Porta*

The official programme of EASDec starts with the Opening Ceremony and a tour of Palazzo del Bo, including the Anatomy Theatre

18.00 - 18.15 Opening Ceremony
Chair: *Professor Massimo Porta*

18.15 - 18.45 Tour of Palazzo del Bo

18.45 Welcome Cocktail
Sala della Basilica

16th MAY 2014, Friday
at Dipartimento Militare di Medicina Legale, Padova

8.30 - 9.00 Registration
*Please note that badges must be worn all the time while on the premises as this is a military property. Please carry a photo ID with you at all times.*

9.00 - 9.15 Introduction
*Professor Edoardo Midena and Colonel Doctor Giuseppe Parise*
SESSION 1
Screening for diabetic retinopathy and beyond...
Chairs: Professor Peter Scanlon and Dr Stela Vujosevic


10.00 - 10.15 Five year progression of diabetic retinopathy in Malawi. S. Harding, P. Burgess, C. Pindani, G. Msukwa, M. Garcia-Finana, T. Allain


10.30 - 10.50 The Professor Anne Katrin Sjolie Prize for best abstract: OCT/photographic clinics for screen positive maculopathy patients. M. Buckle, L. Price, S.Chave, S.J. Aldington, PH. Scanlon

10.50 - 11.20 Coffee and tea break

SESSION 2
Symposium: Corneal nerves as a window to peripheral diabetic neuropathy.
Chairs: Professor Edoardo Midena and Rayaz Malik

11.20 - 11.35 Vincenza Spallone. Peripheral diabetic neuropathy: the scenario

11.35 - 11.50 Edoardo Midena. Corneal confocal microscopy and the peripheral nervous system

11.50 - 12.05 Alfredo Ruggeri. Corneal sub-basal nerve plexus parameters: toward automatic quantification

12.05 - 12.20 Francine Behar-Cohen. The cornea: a sensor of the diabetic eye?

12.20 - 12.40 Rayaz Malik. Corneal nerves in human diabetes

12.40 - 12.50 Discussion

12.50 - 14.30 Lunch and poster session
SESSION 3
Poster session
Moderators: Professors Alan Stitt and Toke Bek


2. Zn$^{2+}$-ions containing in retina formed toxic chelate complexes with diabetogenic derivatives of 8-oxyquinolin.

3. Inhibition of protein tyrosine phosphatase 1B protects against the adverse effects of pro-inflammatory cytokines on IGF-I receptor signalling in the retina.
   Angela M Valverde, Ana I Arroba

4. The oxygen saturation in retinal vessels from diabetic patients depends on the severity and type of vision threatening retinopathy.
   C. Jørgensen, S. Hardarsson, T. Bek

5. Macular dysfunction is common in both type 1 and type 2 diabetic patients without macular edema.
   R. Lattanzio, G. Querques, U. De Benedetto, E. Borelli, L. Querques, G. Maestranzi, F. Bandello

6. Including steered images gives a new perspective to ultra-widefield photography for screening for diabetic retinopathy.
   M. Rasmussen, R. Broe, U. Frydkjaer-Olsen, T. Peto, J. Grauslund

7. En-face optical coherence tomography in diabetic patients.
   S. Bini, S. Vujosevic, M. Berton, E. Midena

   M. Lombardo, M. Parravano, S. Serra, B. Boccassini, M. Varano, G. Lombardo

   C. Gustavsson, M. Dorkhan, L. Groop

10. “Casual” HbA1c levels do not reflect current retinopathy well while cumulative excess HbA1c values (CueA1C) do in younger onset type 1 diabetes.
    A. Hirose, S. Kitano, Y. Uchigata

12. The first Ophthalmology Reading Centre for diabetic retinopathy in Slovakia: a multidisciplinary approach.  
   M. Gajdosova, M. Ondrejkova, E. Martinka

13. Risk of progression to sight threatening retinopathy in R1M1, R2M0, R2M1 cases retained within an annual photographic screening program.  
   J. Smith, F. I. Flynn-Smith

   E. Curtis, A. D. Wright, J. Gibson, M. Clarke, P.M. Dodson

15. Outcome of proliferative diabetic retinopathy referrals from photographic screening programme to Hospital Eye Service.  
   F. Razi, R. M. Muniraju

   T. Magan, A. Kirmani, M. Robertson, M. Mohamed, S. Mann

17. Baseline characteristics of diabetic macular edema patients within the Luminous Study.  
   A. Minnella

   F. Araki, T. Shiraya, S. Kato

19. Repeated intravitreal dexamethasone implant (Ozurdex) for diabetic macular edema.  
   F. Bandello, M. Scaramuzzi, R. Lattanzio, L. Iuliano, R. Sacconi, C. Preziosa, G. Querques

20. The treatment of diabetic macular edema with ranibizumab in young patients with diabetes type 1.  
   J. Stefanickova, P. Krajcova, L. Javorska, P. Mruzkova

   C. M. Eandi, C. Alovisi, M. Nassisi, F. M. Grignolo

22. Intravitreal dexamethasone implant for the treatment of diffuse diabetic macular oedema unresponsive to anti-VEGF therapy.  
   V. Sarao, D. Veritti, P. Lanzetta
SESSION 4
Mechanisms of disease in diabetic retinopathy
Chairs: Professors Reinier Otto Schlingemann and Rafael Simó

14.30 - 14.45  Lp-PLA2 is a potential therapeutic target in diabetic macula edema.

_P. Canning, J. V. Glenn, V. Prise, D. Gale, A. Stitt, P. A. Adamson_

14.45 - 15.00  Inhibition of NO and COX synthesis are possible tools for normalizing diameter changes of retinal vessels in diabetic retinopathy.

_L. Pedersen, T. Bek_

15.00 - 15.15  CTGF is involved in structural retinal vascular changes in long-term experimental diabetes.


_P. S. Jensen, T. Bek_

15.30 - 15.45  Effects of diabetic-like conditions and somatostatin/brimonidine on pericyte-ganglion cell co-culture models.

_E. Beltramo, T. Lopatina, M. Porta_

15.45 - 16.00  Study of the microglia polarity status in Diabetic Retinopathy in db/db mice.

_A. I. Arroba, D. Cazoni, C. Hernandez, R. Simó, P. de la Villa, A. Martinez-Valverde_

**EVA KOHNER LECTURE**

16.00 - 16.45  Professor Elisabeth Agardh
Diabetic retinopathy: more than just a microvascular disease
Introduced by Professor Massimo Porta

16.45 - 17.15  EASDec Business Meeting
Chair: Professor Tunde Peto
SESSION 5
Hot news from clinical trials in diabetic macular edema
Chairs: Professors Simon Harding and Francesco Bandello

9.00 - 9.15  Ranibizumab 0.5 mg treat-and-extend versus pro-re-nata in visual impairment due to diabetic macular edema: RETAIN study.
F. Ricci

S. Vujosevic, M. Casciano, S. Bini, E. Midena

E. Midena for the VIVID-DME/VISTA-DME Study Investigators.

9.45 - 10.00 Critical and practical appraisal of laser in diabetic macular edema.
F. Bandello

10.00 - 10.45  Keynote Lecture
Professor Angelo Avogaro
Pharmacologic approaches to rescue endothelial dysfunction.
Introduced by Professor Edoardo Midena

10.45 - 11.15  Coffee and tea break
SESSION 6
Clinical aspects of diabetic retinopathy
Chairs: Professors Tunde Peto and Teresio Avitabile

11.15 - 11.30 Progressive thinning of inner retinal layer thickness over time in diabetic patients.
R.O. Schlingemann, H.W. van Dijk, P.H.B. Kok, F. W. Wit, J. H. DeVries, M.D. Abràmoff, F.D. Verbraak

11.30 - 11.45 The retinal vascular fractal dimension predicts 16-year microvascular complications in Type 1 diabetes mellitus.
R. Broe, ML. Rasmussen, U. Frydkjaer-Olsen, T. Peto, J. Grauslund

11.45 - 12.00 Severe proliferative diabetic retinopathy treated with vitrectomy or panretinal photocoagulation: a single centre randomised controlled clinical trial.
T. Avitabile, V. Bonfiglio, F. Castiglione, M. Castaing

12.00 - 12.15 Distinct HbA1c trajectories in a type 2 diabetes cohort are associated with a different prevalence of diabetic retinopathy and microalbuminuria.

12.15 - 12.30 Ethnicity and risk of progression to sight threatening diabetic retinopathy in type 2 diabetes – what’s the link?
S. J. Aldington, I. M. Stratton, S. Sivaprasad, C. Connor, E. C. Fletcher, P. H. Scanlon

H. Wharton, K. H. Whitehouse, R. L. Hampshire, N. K. Bilkhu, M. Clarke, A. Syed, A. A. Tahrani

12.45 - 13.00 Best poster prize ceremony and closing remarks
Professor Massimo Porta
GLOBAL OPHTHALMOLOGY AWARDS PROGRAM

BAYER: INVESTING IN RETINAL DISORDERS RESEARCH & EDUCATION

AN INTEGRAL PART OF BAYER’S COMMITMENT TO OPHTHALMOLOGY

The Global Ophthalmology Awards Program (GOAP) is designed to encourage ophthalmologists to develop their skills in retinal disorders, and to fund research initiatives through the disbursement of grants.

The program’s awards are available in two categories:

There are two different award categories available. They offer clinicians and researchers working within ophthalmology options tailored to their aspirations and career backgrounds.

Fellowship Project Award
This award is a mentored award intended to facilitate the development of research and clinical expertise in the field of retinal ophthalmology. This award is for applicants who have completed ophthalmology training and wish to work on a specific research project as part of their training to become a retinal specialist.

- Duration of award: 1 year
- Award: Up to US$50,000*

Research Award
This award supports a wide range of clinical and/or basic research projects. Applicants must have an MD or a PhD and be affiliated with a facility that carries out research in ophthalmology, such as a medical school, university, hospital, treatment center, or laboratory.

- Duration of award: 1 year
- Award: Up to US$50,000*

*In the majority of cases. Awards of up to US$100,000 will be considered. Budgets should be realistic and appropriate to the scope of work being proposed. Payment will be made to the awardee’s institution.

To learn more, visit www.bayer-ophthalmology-awards.com or pick up an Application Guide from our booth.
**SCIENTIFIC SESSIONS**

**Thursday, 15th May**  
Palazzo del Bo  
Via VIII Febbraio 2

**Friday, 16th and Saturday 17th**  
Dipartimento Militare di Medicina Legale  
Via San Giovanni di Verdara 115

**SOCIAL EVENTS**

**Thursday, 15th May**  
Sala della Basilica, Palazzo del Bo  
Via VIII Febbraio 2  
Welcome Cocktail

**Friday, 16th May**  
Palazzo Zacco  
Prato della Valle 82  
Social Dinner

---

**CITY MAP**

- Palazzo del Bo  
  Via VIII Febbraio 2
- Dipartimento Militare di Medicina Legale  
  Via San Giovanni di Verdara 115
- Palazzo Zacco  
  Prato della Valle 82
Innovation and responsibility, at the patient’s service

Global leader in the healthcare industry, Novartis is strongly committed to the research and development of drugs and innovative solutions to treat diseases, reduce the burden of pain and suffering and improve people’s quality of life. With the primary goal of satisfying the needs of patients, by meeting the expectations and respecting the rights of all its stakeholders, Novartis does its best to manage its activities in a sustainable way from a social, environmental and economic point of view. Thanks to its constant focus on innovation and its responsible approach to health requirements and needs, Novartis is a reliable reference point for millions of people, in Italy and all over the world.
“Il presente evento è soggetto a deposito AIFA ai sensi e per gli effetti di cui all’art. 124 del D.Lgs. 219/06.”
LOCAL ORGANIZING SECRETARIAT
Sistema Congressi S.r.l.
Via Trieste, 26 - 35121 Padova, Italy
Phone +39 049 651699
www.sistemacongressi.com

LOCAL SCIENTIFIC COMMITTEE
Professor Edoardo Midena
Dr Stela Vujosevic
Dr Mara Salerno
Department of Neurosciences - Ophthalmology
University of Padova
Via Giustiniani, 2 - 35128 Padova, Italy
Giotto, Scrovegni Chapel, Padua, c. 1305
The Scrovegni Chapel is universally accepted as Giotto’s masterwork. Completed in 1305 for Enrico Scrovegni’s family in Padua, the frescoes adorning the walls and ceiling of the chapel relate a complex, emotional narrative on the lives of Mary and Jesus.

By courtesy of the Municipality of Padova – Department of Culture